Hope Rugo, Medical hematologist-oncologist at UCSF, shared on X/Twitter:
“Fabrice Andre presents DB07. The expected amazing and durable response to first line TDXd +/- Pertuzumab. Adding P almost tripled grade 3 diarrhea rates; no grade 5 ILD. Imp implications for DB09 and great to see this efficacy.”
Source: Hope Rugo/X
